CIK 0001395937
- Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 320162505
- Phone
- +1 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- 4 Grant or award Director acquired 16,000 shares (grant or award)
- 4 Grant or award Director acquired 16,000 shares (grant or award)
- 4 Open-market sale Director sold 39,000 shares at an average $26.84 ($1,046,782)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Scientific Officer sold 25,000 shares at an average $25.04 ($626,025)
- 4 Open-market sale Director sold 29,899 shares at $25.90 ($774,411)
- 4 Open-market sale Chief Executive Officer sold 16,231 shares at $25.29 ($410,508)
- 4 Open-market sale Chief Executive Officer sold 33,769 shares at an average $25.02 ($844,890)
- 4 Open-market sale Director sold 4,101 shares at an average $25.06 ($102,777)
- 4 Open-market sale President, Head of R&D sold 173,988 shares at an average $23.11 ($4,020,056)
- 4 Open-market sale President, Head of R&D sold 279,420 shares at an average $23.64 ($6,604,327)
- 4 Open-market sale Director sold 78,815 shares at an average $24.08 ($1,897,988)
- 4 Open-market sale Chief Scientific Officer sold 25,000 shares at $25.04 ($625,893)
- 4 Open-market sale Director sold 24,000 shares at $23.02 ($552,382)
- 4 Open-market sale Chief Executive Officer sold 31,602 shares at $21.06 ($665,393)
- 4 Open-market sale Chief Executive Officer sold 15,109 shares at an average $21.07 ($318,407)
- 4 Open-market sale President, Head of R&D sold 62,292 shares at $19.00 ($1,183,430)
- 4 Grant or award Chief Financial Officer acquired 3,205 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 5 of 13 · 259 filings